Johnson & Johnson and Varian Medical exited the cancer radiotherapy developer in an upsized initial public offering after $158m in funding.
Fusion Pharmaceuticals, a Canada-based cancer drug developer backed by pharmaceutical group Johnson & Johnson and medical device maker Varian Medical Systems, raised almost $213m when it went public on Friday.
The initial public offering involved the company increasing the number of shares in the IPO from 8.35 million to 12.5 million and pricing them at $17 each, above the $14 to $16 range it had set the previous Monday. It floated on the Nasdaq Global Select Market.
Underwriters Morgan…
